News
Oral Anticoagulants Compared for Gastrointestinal Safety
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
Your search for apixaban returned 74 results
Drugs in the Pipeline
Eliquis Reversal Agent Demonstrates Efficacy in Phase 3 Study
Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).
News
Labeling for Several HIV Meds Updated to Include Interaction Data With DOACs
If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.
News
Prophylaxis With Apixaban Feasible for Cancer Patients
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.
AHA 2015
Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
AHA 2018
Combining NSAIDs With Oral Anticoagulants Increases Bleeding Risk in AF
While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.
News
Apixaban Beats Aspirin for Stroke Prevention in A-Fib
Apixaban is more effective than aspirin in reducing the risk of repeat stroke and systemic embolism in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonists (VKA) therapy.
News
Safety of Direct Oral Anticoagulants Versus Warfarin Investigated
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.
News
AHA: Concentrates Promising for Reversal of Apixaban
Different factor concentrates can reverse some of the alterations in hemostasis attributed to apixaban.
News
Apixaban vs Placebo in VTE Prevention in Cancer Patients Initiating Chemotherapy
Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban vs placebo.
